z-logo
open-access-imgOpen Access
Aminoacylase 1 (ACY-1) Mediates the Proliferation and Migration of Neuroblastoma Cells in Humans Through the ERK/Transforming Growth Factor β (TGF-β) Signaling Pathways
Author(s) -
Zimin Chen,
Jiahui Gao,
Jun Sun,
Zhouguang Wu,
Bin Wang
Publication year - 2020
Publication title -
medical science monitor
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.636
H-Index - 85
eISSN - 1643-3750
pISSN - 1234-1010
DOI - 10.12659/msm.928813
Subject(s) - cell growth , mapk/erk pathway , signal transduction , gene knockdown , biology , neuroblastoma , blot , flow cytometry , cell culture , carcinogenesis , microbiology and biotechnology , transfection , transforming growth factor , cell migration , cancer research , apoptosis , biochemistry , genetics , gene
Background Aminoacylase 1 (ACY-1) is a cytosolic enzyme that catalyzes amino acid deacylation and has been reported to participate in various human diseases. However, the role and mechanism of ACY-1 in neuroblastoma (NB) are not completely understood. The aim of this study was to elucidate the role of ACY-1 in NB. Material/Methods Overexpression and knockdown of ACY-1 in human NB cells were performed, and the transfection efficiency was assessed through fluorescence microscopy, real-time PCR, and western blotting. The effect of ACY-1 on tumorigenesis and metastasis was determined by cell counting, colony formation, wound healing, flow cytometry, and transwell invasion assays in vitro, and the signaling pathway was examined using western blotting. Results ACY-1 overexpression inhibited proliferation and induced apoptosis in human NB cells. ACY-1 inhibited the colony formation ability, migration, and invasion of SH-SY5Y cell lines. Moreover, the ERK1/2 and TGF-β1 signaling pathways were more active when ACY-1 was overexpressed in NB cells. However, the knockdown of ACY-1 in SH-SY5Y cell lines showed the opposite effects. Conclusions ACY-1 regulates the proliferation, migration, and invasion of human NB cells through the ERK1/2 and TGF-β1 signaling pathways, implying that ACY-1 may serve as a therapeutic target for patients with NB.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom